Previous 10 | Next 10 |
-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) t...
An important shareholder is agitating for change at Amarin (NASDAQ: AMRN) . Will this lead to meaningful improvements, or even put the company in play? Some investors are clearly hoping for one of these outcomes, following regulatory filings submitted by both the company and one...
The ADRs of Ireland-based biotech Amarin Corporation (NASDAQ:AMRN) have risen ~6% in the morning hours Friday after activist investor Sarissa Capital Management said it planned to seek representation in the company’s board of directors. It has already conducted discussions wi...
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...
One of the first catalysts to look for when trading penny stocks is news. Company headlines are some of the most prominent and easily accessible pieces of information. In most cases, sporadic moves in the market can be associated with significant updates from companies. Think of it as the f...
Amarin Corporation (NASDAQ: AMRN) , a biopharmaceutical company that specializes in cardiovascular therapies, saw its shares plummet 46.1% in May, according to data from S&P Global Market Intelligence . The stock closed at $2.69 a share on April 29, the last trading day of t...
Amarin Corporation plc (AMRN) H.C. Wainwright Global Investment Conference Call May 25, 2022 12:00 ET Company Participants Karim Mikhail - President & Chief Executive Officer Conference Call Participants Matthew Caufield - H.C. Wainwright & Co. Presentation Matthew Caufield All right,...
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec Canada NewsWire Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease Private drug plan...
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the Americ...
JP Morgan has downgraded Amarin Corp. (NASDAQ:AMRN) to underweight due to headwinds seen in both the U.S. and Europe. The firm also took away its price target. Analyst Jessica Fye said that U.S. volume and pricing pressures could get even worse, while in Europe, reimbursement and pricing in c...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...